In the March issue of Seizure, we read with interest the study by Murphy et al., investigating the prescribing trends of valproate in the women of reproductive age in Ireland (Seizure 2016; 36: 44-48). Again in March, France announced the warning measures for valproate use in the women of reproductive age [2] .
Although dose-dependent structural and neurodevelopmental adverse effects of prenatal valproate exposure in the infants and children are relatively well-studied, an important gap exists regarding how much of this information is translated into clinical practice. The study by Murphy et al. [1] was an important contribution in this context. The authors demonstrated a drop in the overall rate of valproate prescribing in 2013 (3.14/1000) compared to 2008 (3.5/1000) for epilepsy [1] . On the contrary, when other indications such as bipolar disorder and migraine were also considered, the mixed prescribing rate was found to be increasing over this 5-year period. Additionally, the low rates of (10%) folic acid prescription and contraception rates were remarkable [1] . In this letter, we would like to point two relevant studies which support these data, however left unmentioned by Murphy et al.
Using the New York State Medicaid claims data (N = 40.526) in 2009 and excluding the patients with a diagnosis of seizure disorder, Wisner et al. showed valproate was the most frequently prescribed (32.3%, N (total) = 40.526) non-antipsychotic mood stabilizer for the entire sample [3] . In the sub-analysis, valproate was the most frequently prescribed non-antipsychotic mood stabilizer for women in the reproductive age (23.4%, 15-49 years, N (total) = 14.236), although they were less likely to receive a valproate prescription than similarly aged men or older women [3] . In the other study, Wieck et al. [4] conducted an audit in the psychiatric departments of three UK hospitals in order to review the records of female patients in the reproductive age who received psychiatric counseling and a prescription of valproate or carbamazepine for mood disorder. By reviewing the medical records, the authors assessed whether psychiatrists held a discussion with the patient regarding the possible teratogenic risks of antiepileptic medications, her reproductive plans and the current method of contraception. The authors also investigated whether the psychiatrist guided the patient to a family planning clinic or wrote a letter to her general practitioner about it and prescribed folic acid or asked her general practitioner to do so. The results showed that in more than half of the cases the described issues were not mentioned [4] . The psychiatrists recorded that they had discussed the risks and benefits of the antiepileptic medications in only 38% of the cases, while only in 19% of the records showed an evidence that they had explained the possible teratogenic effects clearly. For the reproductive plans (25%) and contraception advice (22%) the rates were similarly low [4] . Only 9% of the patients were prescribed 5 mg folic acid per day [4] , which is comparable with the rate in the study by Murphy et al., [1] . Although the sample size was small (n = 32), this study indicated that the psychiatrists did not provide adequate counseling to women in childbearing age regarding the reproductive issues of antiepileptic medications they prescribed [4] .
In conclusion, as Murphy et al. also stated in the last part of their discussion, the awareness should be raised particularly in nonepilepsy specialists regarding the prescribing risks of valproate in the women of reproductive age [1] . We hope that the recent announcement by France [2] heightens this awareness by inducing other countries to adopt similar measures as soon as possible. Increased surveillance on valproate prescribing trends in women of reproductive age is needed to ensure that the measures are effective.
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